T HE UTERUS IS a classical sex steroid target organ, where both myometrial and endometrial cells express estrogen and progesterone receptors (ERs and PRs). The vascular system is also estrogen responsive (1, 2) . Experimental studies show that 17␤-estradiol exerts a range of direct effects on endothelial cells (EC), which can be either rapid or long-term (3) . These include up-regulation of endothelial nitric oxide synthase activity, modulation of adhesion molecule expression, and promotion of EC survival and angiogenic activity (3) (4) (5) (6) (7) . In contrast, progesterone has proapoptotic effects and inhibits EC proliferation (8) . Because ER and PR have been demonstrated in human large vessel EC (7) (8) (9) and in endometrial MEC (10) , it is likely that sex steroid effects are mediated by these receptors, although estrogen also has nongenomic effects (11) .
The two ERs, ER␣ and ER␤, which are encoded by separate genes, are involved in the vascular actions of 17␤-estradiol, but their relative roles are unclear (1, 12) . ER␣ and ER␤ bind 17␤-estradiol with similar high affinity causing receptor dimerization. They act as ligand-activated transcription factors for a range of estrogen target genes, binding to estrogen response elements or indirectly by interaction with other DNA binding proteins (13) . However, ER␣ and ER␤ can mediate opposing transcriptional activities, dependent on the type of response element in target gene promoters and other cell specific factors such as presence or absence of coregulators (12) . There are also differences in the tissue distribution of ER␣ and ER␤, although there is considerable overlap and heterodimerization may occur in cells where they are coexpressed.
Vascular endothelial growth factor (VEGF) is a specific mitogen for EC, acting through two tyrosine-kinase receptors, VEGF receptor (VEGFR)-1 (flt-1) and VEGFR-2 (KDR), expressed almost exclusively on EC (14) . Both receptors bind VEGF with high affinity, but signaling through VEGFR-2, rather than VEGFR-1, mediates the angiogenic effects of VEGF (14) . Both VEGFRs are expressed at low levels in vivo and in quiescent cultured EC (15, 16) where they serve to promote EC survival (17) but are up-regulated during periods of angiogenesis (18) . The factors regulating VEGFR exAbbreviations: bFGF, Basic fibroblast growth factor; CDS, Cell Dissociation Solution; ch, charcoal stripped; EC, endothelial cell(s); ER, estrogen receptor; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; HRP, horseradish peroxidase; HS, human serum; MEC, microvascular endothelial cell(s); MFI, mean fluorescence intensity; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulpho-phenyl)-2H-tetrazolium; PE, phycoerythrin; PR, progesterone receptor; rh, recombinant human; R S , Spearman rank correlation coefficients; TBST, Tris-buffered saline-Tween 20; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; VSMC, vascular smooth muscle cells.
pression are not fully understood, although hypoxia and some cytokines and growth factors may be involved (14) .
17␤-estradiol is known to modulate the expression of some growth factors and their receptors (19) . Because 17␤-estradiol up-regulates basic fibroblast growth factor (bFGF)-induced angiogenesis (6, 7, 10) we postulated that 17␤-estradiol and progesterone would also modulate VEGF-induced angiogenesis through alteration of VEGFR expression. While the study of sex steroid effects on endothelium has largely focused on large vessels, there are few studies examining the effects of 17␤-estradiol and progesterone on MEC derived from classic sex steroid-responsive tissues such as the uterus. We have used MEC isolated from the human myometrium as an in vitro model to investigate the effects of estrogen on the microvascular system. Here we demonstrate that 17␤-estradiol up-regulates VEGFR-2 expression in myometrial MEC. We also show that myometrial MEC express both ER␣ and ER␤ and that 17␤-estradiol up-regulation of VEGFR-2 is associated with ER␣ expression.
Materials and Methods Materials
Fetal calf serum (FCS) (CSL, Melbourne, Australia) and male human serum (HS) (Victorian Red Cross Blood Service) were charcoal-stripped (ch-FCS, ch-HS) for hormone experiments and contained less than 1 pg/ml 17␤-estradiol by RIA. 17␤-estradiol, progesterone, and Cell Dissociation Solution (CDS) were from Sigma-Aldrich (St. Louis, MO). Recombinant human (rh) VEGF 165 , biotinylated rhVEGF 165 , biotinylated soybean trypsin inhibitor, RDF buffer and avidin-fluorescein isothiocyanate (avidin-FITC) were purchased as a kit from R&D Systems (Minneapolis, MN). Mouse antihuman CD31 was from DAKO Corp. (Carpinteria, CA), mouse antihuman ER␣ was from Novocastra Laboratories, Ltd. (Newcastle upon Tyne, UK) and rabbit antihuman ER␤ (catalog no. PAI-313) was from Affinity BioReagents, Inc. (Golden, CO) Phycoerythrin (PE)-labeled sheep anti-IgG (Fab'2 fragments) were from Silenus (Victoria, Australia), whereas horseradish peroxidase (HRP)-conjugated sheep anti-IgG was from Zymed Laboratories, Inc. (San Francisco, CA). Western blotting reagents, Blot-Quickblocker, femto/Trisbuffered saline-Tween 20 (TBST) and femtoLUCENT chemiluminescence detection system were from Chemicon (Temecula, CA). CellTitre 96 MTS [3-4,5- 
Human tissues
Human myometrial tissue was obtained from 35 ovulating women (aged 27-53 yr) who had not taken exogenous hormones in the previous 3 months and underwent hysterectomy for uterine prolapse or fibroids (benign tumor of the myometrium). Informed consent was obtained from each patient, and ethical approval was obtained from Monash Medical Centre Human Research and Ethics Committee B. Many of the hysterectomy samples contained fibroids, which are easily recognized by their well circumscribed border, and were removed before processing. The tissue was collected in HEPES-buffered M199 medium, containing 10% FCS and antibiotic-antimycotic solution (final concentrations: penicillin 10 6 U/liter, streptomycin 10 6 U/liter and fungizone 2.5 mg/liter), stored overnight at 4 C, and then processed.
Microvascular EC culture
Myometrial tissue was dissociated with collagenase and deoxyribonuclease, followed by a short trypsin treatment to produce single cell suspensions, and MEC were isolated by positive selection with Ulex europeaus agglutinin-1-coated Dynabeads (Dynal, Oslo, Norway) as described (20) . MEC were then seeded into fibronectin-coated tissue culture flasks (10 mg/liter) and cultured in M199 medium containing 15% HS/5% FCS, 2 mmol/liter glutamine, 5 g/liter bFGF, 100 mg/liter heparin, and antibiotic/antimycotic solution as described (20) . On subsequent passages, MEC were repurified with Ulex europeaus agglutinin-1-coated Dynabeads and were used for all analyses between passages 1-3; purity was more than 99% by flow cytometry of CD31-immunolabeled cells. Not all analyses were performed on each isolate, due to insufficient numbers of highly purified MEC obtained from some samples.
Flow cytometric analysis of rhVEGF 165 binding to myometrial MEC
Confluent MEC cultures in six-well plates were incubated for 48 h in hormone-free medium (phenol red-free M199 with 15% ch-HS/5% ch-FCS, 10 ng/ml VEGF 165 , and 100 mg/liter heparin) and then quiesced in HS-free phenol red-free M199 containing 5% ch-FCS, 10 g/liter VEGF 165 and 100 mg/liter heparin for 24 h. We have previously established that myometrial MEC do not proliferate in 5% FCS containing VEGF (20) . MEC were then stimulated with 17␤-estradiol, progesterone, or 17␤-estradiol and progesterone in HS-free medium containing 0.5% BSA, 10 g/liter VEGF 165 , and 100 mg/liter heparin. In some experiments, 5% ch-FCS was substituted for 0.5% BSA in the HS-free medium. Preliminary experiments showed that it was necessary to include VEGF in human serum-free medium to prevent MEC apoptosis and obtain basal rhVEGF 165 binding. Control samples were incubated with vehicle. MEC were harvested in CDS, washed, and resuspended in RDF buffer. Aliquots (25 l; 5 ϫ 10 4 cells) were incubated with saturating amounts of biotinylated-rhVEGF 165 (30 ng) and anti-CD31 (4 mg/liter) for 1 h at 4 C, followed by 10 l avidin-FITC for 30 min at 4 C. Cells were washed and then incubated with PE-conjugated antimouse IgG (1/100) for 30 min at 4 C. Nonspecific binding was assessed by substituting biotinylated soybean trypsin inhibitor (same biotin:protein ratio) for biotinylated-rhVEGF 165 , and CD31 with isotype matched IgG at equivalent concentrations (negative control). Samples were analyzed using a MoFlo flow cytometer (Cytomation, Fort Hills, CO) equipped with an argon laser (Cytomation) and Cyclops Summit software (Cytomation). Two parameter histograms of FITC-VEGF and PE-CD31 were used to determine mean fluorescence intensity (MFI) of VEGF binding on more than 5000 CD31
ϩ MEC per sample. The negative control MFI was subtracted from the respective sample MFI.
Analysis of mRNA for ER␣ and ER␤ by RT-PCR and Southern blotting
Total RNA was prepared from highly purified cultured MEC (Ͼ99%) using the QIAGEN RNeasy Mini Kit. One microgram of total RNA was reverse transcribed and amplified using universal primers for both ER␣ and ER␤ (sense primer: 5Ј-CCG GAA TTC TTC/T GAC ATG CTC/G CTGG; antisense primer: 5Ј-GAT GC/TT CCA TGC CC/TT TGT TAC TC) and for ␤ 2 -microglobulin (sense primer: 5Ј-TGA ATT GCT ATG TGT CTG GGT-3Ј; antisense primer: 5Ј-CCT CCA TGA TGC TGC TTA CAT-3Ј) in a single stage PCR for 30 cycles as previously described (21) . PCR products were probed with gene-specific 32 P-labeled probes (ER␣ probe: 5Ј-GGT TGT GTG CCT CAA ATC TAT TAT TT; ER␤ probe: 5Ј-ATA TCT CTG TGT CAA GGC CAT GA) as described (21) .
ER␣ expression by flow cytometry
The presence of ER␣ receptors was determined in MEC suspensions by microwave permeabilization (22) and flow cytometry (23) . MEC were harvested with trypsin (0.025%), washed and 10 6 cells fixed in 2% paraformaldehyde for 30 min at 4 C, washed and resuspended in 0.01 mol/ liter citrate buffer, pH 6.0, and microwaved for 30 sec on High (500W), washed and resuspended in PBS/1% FCS. Aliquots (50 l; 5 ϫ 10 4 cells) were incubated with 7 mg/liter anti-ER␣ in 10% goat serum for 60 min at 4 C, washed and incubated with PE-antimouse IgG in 10% goat serum for 30 min at 4 C and examined by flow cytometry. The MFI of single parameter histograms of more than 5000 cells was obtained, the MFI of IgG controls subtracted, and the percentage of positive cells with flu-orescence intensity more than 98% of control cells determined. For the negative controls, mouse IgG 1 (7 mg/liter) was substituted for primary antibody. ER␣ positive (MCF-7 or T47D) and negative (MDA-DB-453) control cells were analyzed in each batch.
Western blot analysis for ER␣ and ER␤
MEC lysates (20 g protein) were denatured in SDS sample buffer, separated by 8% SDS-PAGE and transferred electrophoretically to nitrocellulose membranes (Bio-Rad Laboratories, Inc., Hercules, CA). Membranes were blocked in 5% Blot-QuickBlocker for 30 min at 22 C, incubated for 90 min at 22 C with ER␣ antibody (0.93 mg/liter) in femto/TBST buffer or ER␤ (1 mg/liter) in femto/TBST/2% Blot-QuickBlocker, followed by incubation for 60 min at 22 C with HRP-antimouse IgG (1/2000 in femto/PBS Tween 20) for ER␣ or HRP-antirabbit IgG (1/3000 in femto/TBST/2% Blot-QuickBlocker) for ER␤, and detected by femtoLUCENT chemiluminescence system.
Flow cytometric analysis of VEGFR-1 and VEGFR-2 expression on myometrial MEC
MEC were cultured in T25 flasks, incubated with hormone-free medium, quiesced in human serum-free medium, and incubated with 0 (vehicle), 1, and 10 nmol/liter 17␤-estradiol as described for rhVEGF 165 binding. MEC were harvested in CDS and analyzed for rhVEGF 165 binding as described, as well as VEGFR-1 and VEGFR-2 expression by flow cytometry. Aliquots (50 l; 5 ϫ 10 4 MEC) were incubated with 20 mg/liter anti-VEGFR-1 or 10 mg/liter anti-VEGFR-2 in PBS containing 10% goat serum for 60 min at 4 C, washed, and incubated with PEantimouse IgG in 10% goat serum for 30 min at 4 C and examined by flow cytometry. The MFI of single parameter histograms of more than 5000 cells was obtained and the MFI of IgG controls subtracted. For negative controls, mouse IgG 1 (10 or 20 g/ml) was substituted for primary antibody. CEM-A7R cells served as negative control cells, and the MFI for both VEGFR-1 or VEGFR-2 antibodies was the same as the IgG control.
MEC proliferation assay
MEC proliferation was assessed using the CellTitre 96 MTS bioassay (Promega Corp.) as previously described (20) . Briefly, MEC (4 ϫ 10 3 ) were seeded in triplicate into wells of a 96-well plate, made quiescent, and then incubated at 37 C in 5% CO 2 with or without 17␤-estradiol (10 nmol/liter) in phenol-red free M199 medium containing 2 g/liter VEGF and 5% ch-HS/15% ch-FCS in the presence or absence of ICI 182,780 (1 mol/liter) added 1 h before 17␤-estradiol, with medium changes every 2 d. After 6 d incubation, medium was changed to M199/5% ch-FCS, 20 l MTS reagent added and incubated for 2 h at 37 C. Absorbance was then measured at 490 nm using a plate reader.
Statistical analysis
Data were analyzed using two-tailed t test or one-way ANOVA, followed by Dunnett's test for comparison between samples and control using PRISM (GraphPad Software, Inc., San Diego, CA). Correlations were performed using least squares regression analysis and Spearman rank correlation coefficients (R S ) were determined using SPSS version 10.0 (SPSS, Inc. Australasia, North Sydney, Australia). The association between estrogen responsiveness and ER␣ expression was examined by Fisher's exact test using SPSS.
Results

Effect of sex steroids on rhVEGF 165 binding to myometrial MEC
The effect of 17␤-estradiol and progesterone on VEGFR expression was examined on confluent, quiescent myometrial MEC in sex steroid hormone-free minimal medium using a ligand binding assay and flow cytometry. Under these conditions, the level of biotinylated-rhVEGF 165 binding to myometrial MEC represented basal VEGFR expression and was less than nonconfluent, proliferating MEC (Fig. 1A) . MEC incubated with 17␤-estradiol (10 nmol/liter), but not progesterone (100 nmol/liter), bound more biotinylated-rh-VEGF 165 than vehicle-treated control cells (basal binding), demonstrated by an increase in fluorescence intensity (Fig.  1A) . Figure 1B shows that 10 nmol/liter 17␤-estradiol significantly increased VEGF 165 binding (P ϭ 0.01). In contrast, progesterone (100 nmol/liter) alone had no effect on VEGF 165 binding and when progesterone was incubated with 17␤-estradiol, there was a nonsignificant reduction of approximately 60% in the 17␤-estradiol-induced increase. Basal rhVEGF 165 binding and the 17␤-estradiol effect on rhVEGF 165 binding to myometrial MEC were variable between isolates, with a significant proportion that were unresponsive (Table  1) . For characterizing the effect of 17␤-estradiol on rhVEGF 165 binding, our experiments were limited to 17␤-estradiol-responsive MEC isolates, and we did not further study the effect of progesterone.
The 17␤-estradiol-induced increase in rhVEGF 165 binding to myometrial MEC was time dependent, commencing after 1 h incubation, reaching significance at 3 h and maximal at 18 h ( Fig. 2A) . Incubation times greater than 18 h were not studied as MEC began to undergo apoptosis with prolonged incubation in HS-free conditions. 17␤-estradiol also increased rhVEGF 165 binding in a dose-dependent manner, reaching a maximum between 0.1 and 10 nmol/liter (Fig. 2B) . The concentration-response curve was biphasic, and at higher 17␤-estradiol concentrations the effect was reduced. The 17␤-estradiol concentration giving maximal rhVEGF 165 binding varied between isolates and would peak at 0.1, 1, or 10 nmol/liter 17␤-estradiol for any given MEC isolate. We therefore used two 17␤-estradiol concentrations (0.1 or 1, and 10 nmol/liter) to further examine 17␤-estradiol-stimulated increase in rhVEGF 165 binding.
Myometrial MEC express ER␣ and ER␤ mRNA and protein
To determine whether the 17␤-estradiol effect on rh-VEGF 165 binding was associated with ER expression, we examined highly purified responsive and nonresponsive MEC (Ͼ99% CD31 ϩ ) by semiquantitative RT-PCR using primers specific for human ER␣ and ER␤. Figure 3 shows Southern blots of nine myometrial MEC isolates examined. All expressed ER␤ as the major transcript, whereas ER␣ was expressed at lower and more variable levels. Figure 3 shows that ER␣ is expressed in 5/9 of the MEC cultures, specifically samples 3-5, 7 and 9. This ER␣ expression was not due to contaminating myometrial smooth muscle cells, which only expressed ER␣ (24) because ER␣ expression was still observed after FACS sorting CD31-labeled MEC (Fig. 3, sample  9 ). MEC expression of ER␣ and ER␤ transcripts was observed from passages P1 to P7 in four different MEC isolates (24) .
The presence of ER␣ and ER␤ protein in 17␤-estradiolresponsive and -nonresponsive myometrial MEC was then examined by flow cytometry and Western blotting. Figure  4A shows flow cytometric traces from two representative MEC samples, one expressing ER␣ protein shown by a rightward shift in MFI. Low level and variable expression of ER␣ protein was observed in 4/8 samples (Fig. 4, A and B) . Western blotting confirmed the variable expression of ER␣ in myometrial MEC isolates, showing a band at approximately 67 kDa, the expected molecular size for human ER␣ protein (Fig. 4C) . ER␤ protein was examined by Western blotting, because highly specific ER␤ antibodies suitable for flow cytometry are not yet commercially available (25) . In all MEC isolates examined, the long form of ER␤ (26) was present, demonstrated by a band at around 59 kDa (Fig. 4C) . There was correspondence in ER␣ expression in the 8/9 MEC samples examined at both mRNA and protein level (Figs. 3 and  4 , and data not shown).
17␤-estradiol-mediated increase in rhVEGF 165 binding is associated with ER␣ expression
There was a strong association between ER␣ expression in myometrial MEC and the ability of 17␤-estradiol to increase rhVEGF 165 binding. 17␤-estradiol increased rh-VEGF 165 binding in 9 of the 16 MEC samples, and in 7 of these, ER␣ mRNA and/or protein was also expressed. Of the seven samples that failed to respond to 17␤-estradiol, six did not express ER␣ mRNA and/or protein, and only one was ER␣ positive. Contingency table analysis of this data (Table 1 ) demonstrates a significant relationship between 17␤-estradiol-mediated increase in rhVEGF 165 binding in MEC for both ER␣ mRNA expression (P ϭ 0.03) and ER␣ protein expression (P ϭ 0.025). However, ER␤ mRNA and/or protein was expressed in all MEC samples examined, whether or not they responded to 17␤-estradiol (Table 1) .
17␤-estradiol increases VEGFR-2 expression in ER␣ positive myometrial MEC
rhVEGF 165 binds to both VEGFR-1 and VEGFR-2, and we wished to determine whether the increased rhVEGF 165 binding was due to 17␤-estradiol up-regulation of one or both receptors. We examined the effect of 17␤-estradiol on VEGFR-1 and VEGFR-2 surface protein expression by flow cytometry using a specific monoclonal antibody to each receptor and compared this expression with 17␤-estradiolinduced rhVEGF 165 binding on four ER␣ positive and six ER␣ negative MEC samples. Figure 5A shows representative flow cytometry traces of VEGFR-2 expression in an ER␣-expressing (ER␣ϩ) MEC sample and an ER␣ negative Figure 5B shows that 17␤-estradiol (1 and 10 nmol/liter) significantly increased VEGFR-2 expression by approximately 25% compared with vehicle in ER␣ϩ MEC. Similarly, 17␤-estradiol significantly increased rhVEGF 165 binding by 25%. In contrast, 17␤-estradiol had no stimulatory effect on rhVEGF 165 binding or VEGFR-2 expression in ER␣ negative MEC samples (Fig. 5C) . Rather, 17␤-estradiol decreased rhVEGF 165 binding and VEGFR-2 expression in these ER␣ negative MEC samples. There was a significant correlation between the effect of 17␤-estradiol on rhVEGF 165 binding and VEGFR-2 expression in both ER␣ϩ and ER␣Ϫ MEC samples (R S ϭ 0.66, P ϭ 0.03, n ϭ 10; and R S ϭ 0.71, P ϭ 0.047, n ϭ 10) for 1 and 10 nmol/liter 17␤-estradiol, respectively. 17␤-estradiol had no effect on VEGFR-1 expression in ER␣ positive or negative MEC samples (results not shown).
The ER antagonist ICI 182,780 inhibits 17␤-estradiolmediated increase in rhVEGF 165 binding and 17␤-estradiol-augmentation of VEGF-induced MEC proliferation
The role of ER in 17␤-estradiol-mediated increase in rhVEGF 165 binding was examined on 17␤-estradiol-responsive MEC isolates using an ER antagonist, ICI 182,780, which blocks the action of both ER␣ and ER␤ (27) . MEC isolates were incubated with a maximal 17␤-estradiol concentration (0.1 or 10 nmol/liter) in the presence and absence of 100-fold molar excess ICI 182,780, and rhVEGF 165 binding was measured. Figure 6A shows that ICI 182,780 significantly inhibited 17␤-estradiol-induced VEGF-binding (P Ͻ 0.05), suggesting that the increase in rhVEGF 165 binding induced by 17␤-estradiol was mediated via ER.
Because 17␤-estradiol increased both rhVEGF 165 binding and VEGFR-2 expression, we examined whether 17␤-estradiol increased the proliferative response of ER␣ϩ myometrial MEC grown under suboptimal conditions (VEGF, 2 g/liter and serum, 5% ch-HS/15% ch-FCS) (20) . Figure 6B shows that 10 nmol/liter 17␤-estradiol augmented VEGFstimulated MEC proliferation, and this effect was also inhibited by 100-fold molar excess ICI 182,780.
Discussion
A major finding of the present study was that 17␤-estradiol, but not progesterone, increased VEGFR expression in human myometrial MEC as measured by changes in the level of ligand (rhVEGF 165 ) binding. We found that this response to 17␤-estradiol was highly variable between subjects and was mediated by ER. A second major finding was that MEC isolated and cultured from human myometrium, a classic sex steroid-responsive tissue, consistently expressed ER␤, whereas the expression of ER␣ was low and variable between subjects. Thirdly, we found a strong association between ER␣, but not ER␤, expression in myometrial MEC and their ability to respond to 17␤-estradiol by increasing rhVEGF 165 binding. Finally, we demonstrated that the increased rhVEGF 165 binding correlated with increased VEGFR-2 expression.
17␤-estradiol up-regulation of VEGFR-2 expression in human myometrial MEC
In the present study, we showed that approximately 60% of human myometrial MEC samples responded to 17␤-estradiol with an increase in rhVEGF 165 binding. This effect of 17␤-estradiol was both time and concentration dependent. 17␤-estradiol elicited a maximal increase in rhVEGF 165 binding that includes physiological plasma concentrations for reproductive age women (0.1-2.2 nmol/liter). The response to 17␤-estradiol concentration was biphasic, and the peak concentration varied between individual MEC isolates. Similarly, Suzuma et al. (28) demonstrated that 17␤-estradiol specifically increased VEGFR-2 mRNA expression in a biphasic manner over a similar time frame in bovine retinal EC. Data from the present study using VEGFR-specific antibod- ies suggest that 17␤-estradiol up-regulates VEGFR-2 rather than VEGFR-1 expression. 17␤-estradiol enhancement of VEGF-induced MEC proliferation observed in the present study and that of Suzuma et al. (28) may be a direct consequence of an estrogen-mediated increase in VEGFR-2 expression because EC proliferation is dependent on VEGFR-2 rather than VEGFR-1 signaling (29) . Alternatively, 17␤-estradiol may have an indirect effect on VEGFR-2 expression by increasing VEGF secretion from EC (28) because VEGF gene transcription is regulated by 17␤-estradiol (30) . VEGF up-regulates its own receptor, VEGFR-2 (31), although this response was only observed after 24 h (18, 28, 31 ). 17␤-estradiol augmentation of bFGF-stimulated EC proliferation is an indirect response, resulting from 17␤-estradiol stimulation of bFGF secretion by EC (32) . Together, these studies suggest that 17␤-estradiol enhances angiogenesis by augmenting EC proliferation stimulated by two of the most significant angiogenic growth factors, VEGF and bFGF, although different mechanisms maybe involved (6, 28, 32, 33) . The 17␤-estradiol enhancement of VEGFR-2 expression and subsequent proliferative effect mediated by VEGF in myometrial MEC may be important for the expansion of the myometrial microvasculature that undoubtedly occurs during myometrial growth associated with pregnancy and in vascular remodeling associated with placentation. It is uncertain whether 17␤-estradiol promotion of angiogenesis is limited to vascular beds of sex steroid-responsive tissues or occurs throughout the vasculature. This effect of 17␤-estradiol has been observed in a range of EC in vivo and in vitro. For example, 17␤-estradiol augments EC proliferation in human coronary artery EC, umbilical vein EC (6, 7), myometrial MEC, and bovine retinal EC (28) . 17␤-estradiol also promotes angiogenesis in bFGF-impregnated Matrigel plugs implanted sc in mice, where dermal MEC sprout, proliferate and migrate into the plug (6, 33) .
The cardiovascular protection afforded by estrogen replacement therapy may be to promote an EC proliferative response by up-regulating VEGFR-2 when vessel endothelium is damaged. This effect may not just be confined to large vessels but may contribute to protection of endothelium in other tissues, sensitizing EC to low levels of angiogenic growth factors by up-regulating VEGFR-2. In fact, topical 17␤-estradiol promotes wound healing in the aged, in whom it is typically delayed and in whom circulating 17␤-estradiol levels are low (34) . The lack of response by myometrial MEC to progesterone, together with the diminished response observed with 17␤-estradiol and progesterone, may explain why the inclusion of progesterone in hormone replacement therapy is not as beneficial as a cardiovascular protective agent as estrogen alone (35) .
ER␣ and ER␤ expression in human myometrial MEC
The second major finding of this study was that cultured myometrial MEC constitutively express ER␤, whereas ER␣ expression was variable between subjects. This is the first study that has examined ER␣ and ER␤ expression in purified human MEC in a cohort of subjects large enough to detect the level of variability observed for ER␣ expression. We found that ER␣ (when present) and ER␤ mRNA expression was consistently demonstrated for up to seven passages. Others have demonstrated ER in human large vessel and endometrial MEC, but the specific type of ER was not determined (7, 9, 10) . In an immunohistochemical study of human tissues, the great vessels were both ER␣ and ER␤ positive (36) , whereas others found cultured umbilical vein EC expressed ER␤, but not ER␣ mRNA (37, 38) . However, in immunohistochemical studies of myometrial tissue, ER␤ but not ER␣ was demonstrated in rat EC (39) , but in mouse and rhesus monkey, both ER␣ and ER␤ were expressed (40, 41) . Together, these studies indicate that ER␤ expression may be constitutive in large and microvessel EC and that ER␣ expression is variable and may depend on EC phenotype and the conditions under which they were evaluated.
Role of ER␣ and ER␤ in 17␤-estradiol up-regulation of VEGFR-2 in human myometrial MEC
A major finding of the present study was the significant association between ER␣ expression and the ability of myometrial MEC to functionally respond to 17␤-estradiol by increasing rhVEGF 165 binding and VEGFR-2 expression. While our data on ER expression is only semiquantitative, it is striking that in general those samples expressing ER␣ responded to 17␤-estradiol, whereas those lacking ER␣ failed to respond. This, together with the time taken (several hours) for 17␤-estradiol to elicit this response, and its inhibition by the antiestrogen, ICI 182,780, provides three lines of evidence suggesting that the 17␤-estradiol-mediated increase in VEGFR-2 expression is genomic and mediated by ER, most likely ER␣. It is uncertain whether the 17␤-estradiol-induced increase in VEGFR-2 expression in bovine retinal EC was mediated by ER, because the effect of an ER antagonist was not examined (28) . It is possible that 17␤-estradiol via ER␣ directly regulates VEGFR-2 expression, because the VEGFR-2 promoter contains 5 Sp1 binding sites (42) and is regulated by the Sp1 transcription factor (43) . Furthermore, 17␤-estradiol activates gene transcription through interaction with Sp1 proteins via ER␣, but not ER␤ (44) .
The variable expression of ER␣ in myometrial MEC, as well as the variability in functional response to 17␤-estradiol, suggests that other factors may influence these parameters. However, we have found no relationship between age of patient, indication for hysterectomy (mainly fibroids), stage of menstrual cycle when hysterectomy was performed, or the ability of MEC to grow well in culture, and ER␣ expression. Although MEC were obtained from the inner two thirds of the myometrium (20) , because the inner layers show greater sex steroid responsiveness (45) , it is possible that sampling different sites of the uterine wall may influence ER␣ expression. It will be important to determine whether similar variability in ER␣ expression occurs in other vascular beds and in particular in the large vessels commonly affected by atherosclerosis. Similar variability in ER expression was observed in a study of cultured vascular smooth muscle cells (VSMC) from human coronary arteries, where 53% of subjects expressed ER (46) . While this study could not examine for ER␣ and ER␤ expression, the authors did find a significant association between VSMC expression of ER and the absence of atherosclerosis in premenopausal women. These data, together with our own, raise interesting clinical questions of whether such a correlation exists between MEC expression of ER␣ in our cohort of patients, and whether the vascular response of these women to estrogen replacement therapy would also vary. With respect to the myometrial microvasculature, variable ER␣ expression may result in the variable degrees of uterine atrophy observed in women taking hormone replacement therapy, because the microvasculature may regulate tissue mass (47) .
We have demonstrated a significant association between ER␣ expression and the functional response mediated by 17␤-estradiol, but definitive proof awaits the use of ligands or antagonists with sufficient specificity for ER␣ and ER␤. Much research is being devoted to the identification of such specific ligands; however, those currently available are not of sufficient specificity (48) for testing in MEC coexpressing both ER␣ and ER␤. Because ER␣ and ER␤ can heterodimerize (49) , and ER␤ can operate as a negative regulator of target gene transcription in a promoter-dependent manner (25, 49) , the ratio of ER␤:ER␣ may be more important in determining the final outcome of 17␤-estradiol effects on myometrial MEC and EC in general. In human VSMC, where ER␤ predominates, the ratio of ER␤:ER␣ varied considerably between individuals (25) . It remains to be determined whether the ER␤:ER␣ ratio is similar for EC and VSMC in a given vascular bed for an individual and whether the function of target genes in these two vascular cell types are altered similarly. Differences already exist, because 17␤-estradiol has opposing activities on EC and VSMC proliferation (2, 6, 7, 28, 41, 50) . Studies from ER␣ knockout mice suggest that 17␤-estradiol-dependent angiogenesis and re-endothelialization involve ER␣ (33, 51) , but that ER␤ is important in vascular response to injury, which involved both VSMC and EC (50, 52) . It is likely that the cardiovascular protective effect of estrogen results from multiple effects of 17␤-estradiol on different cellular components of the blood vessel wall, which in turn are dependent on complex interactions between ER␣ and ER␤, the response elements present in target genes and the complement of coregulators in both cell types. Although 17␤-estradiol may have different functional responses on EC and VSMC, these actions may together contribute to the cardiovascular protection afforded by 17␤-estradiol. The level of protection may be quite different between individuals, depending on the level of endothelial ER␣ expression, which is expected to affect uterine MEC and may involve the entire vasculature.
